Patent ID: 7812044
Filing Date: 2010-10-12
Classification: A61K,A61P

Abstract:
1. A method for treating hormone-independent prostate cancer, which comprises administering a combination of a non-peptidic compound having an angiotensin II antagonism selected from the group consisting of 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid and 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate, or a salt thereof, and a LH-RH agonist or antagonist selected from the group consisting of leuprorelin, goserelin, buserelin, triptorelin, nafarelin, histrelin, deslorelin, meterelin, gonadrelin and a peptide represented by the formula: wherein X denotes N(4H 2 -furoyl)Gly or NAc, A denotes a residue selected from NMeTyr, Tyr, Aph(Atz) and NMeAph(Atz), B denotes a residue selected from Dlys(Nic), DCit, Dlys(AzaglyNic), DLys(AzaglyFur), DhArg(Et 2 ), DAph(Atz) and DhCi, C denotes Lys(Nisp), Arg or hArg(Et 2 ), or a salt thereof to a mammal having hormone-independent prostate cancer in an amount effective to treat hormone-independent prostate cancer.